Eliem Therapeutics Inc

+0.01 (+0.40%)
Earnings Announcements

Eliem Therapeutics Reports Q3 Loss Of $0.37 Per Share

Published: 11/14/2022 11:25 GMT
Eliem Therapeutics Inc (ELYM) - Eliem Therapeutics Reports Third Quarter Financial and Business Highlights.
Cash Runway Expected to Fund Operations Into 2025.
Positioned to Initiate Etx-155 Phase 2a Trial in Major Depressive Disorder in Q1 of 2023 With 60-milligram Dose.
Progressing Ind-enabling Studies for Two Kv7 Pre-candidates With Safety Studies Planned in Q1 of 2023.
Qtrly Loss per Share $0.37.
Q3 Earnings per Share View $-0.43 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.38

More details on our Analysts Page.